| Assessment Status | Pre submission consultation scheduled |
| HTA ID | 23064 |
| Drug | Tebentafusp |
| Brand | Kimmtrak® |
| Indication | Tebentafusp is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. |
| Assessment Process | |
| Rapid review commissioned | 10/10/2023 |
| Rapid review completed | 13/11/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tebentafusp compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/11/2023 |
